WHO ICTRP trial
Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of…
NL-OMON45825 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON45825 |
|---|---|
| Public title | Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson*s disease patients with refractory visual hallucinations |
| Scientific title | Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson*s disease patients with refractory visual hallucinations - Apomorphine in PD patients with visual hallucinations: a RCT |
| Primary sponsor | Universitair Medisch Centrum Groningen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | parkinsonism Parkinson's disease;10028037;parkinsonism;Parkinson's disease |
| Interventions | Patients will be treated with either apomorphine 5 mg/ml or placebo (saline) for four weeks. Apomorphine will be infused subcutaneously during the waking day using a apomorphine pump. Titration of apomorphine will be conducted by telephone… |
| Registration date | Jun 21, 2017 |
| Target size | 35 |
| Secondary IDs | 2016-000102-11;NCT02702076;NL55949.042.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: